The advancing research highlights the need for plasma donations from those who have recovered from COVID-19.

According to the CoVIg-19 Plasma Alliance, which includes co-founder Takeda and other leading plasma companies, the first patient is being treated with CoVIg-19, a hyperimmune globulin (H-Ig) medicine that is manufactured at Takeda and other sites from plasma donated by people who have fully recovered from COVID-19. This convalescent plasma contains antibodies against the virus.